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Role of the Innate Immune Response in Tissue Engineered Vascular Graft Stenosis 
Dane Mejias, Narutoshi Hibino, Tai Yi, Yuji Naito, Nicholas Pietris, Jamie Harrington, 
Edward McGillycuddy, Christopher Breuer, Interdepartmental Program of Vascular 
Biology and Therapeutics, Yale University School of Medicine, New Haven, CT 
 
Tissue Engineered Vascular Grafts (TEVGs) hold great promise in advancing the field of 
pediatric cardiac surgery and other applications in which a vascular conduit is required. 
The first human clinical trial of these grafts indicated that stenosis was the primary 
mode of graft failure. Here, we investigate the role of the immune response in stenosis 
through a CB17 murine inferior vena cava interposition model. We demonstrate that 
this mouse model undergoes a dramatic stenotic response, and that this is nearly 
completely abolished in a SCID/bg immunodeficient variant (average luminal diameter 
(LD) WT: 0.071+/-0.035mm, SCID/bg: 0.804+/-0.039mm; P<0.001). SCID-only mice, 
which lack T- cells and B-cells, undergo stenosis with luminal diameters approaching 
those of wild type mice. The bg mutation is characterized by defects in natural killer 
(NK) cell and platelet dysfunction, and treatment of wild-type mice with either anti-
platelet therapy (aspirin/clopidogrel) or an anti- natural killer cell antibody (NK 1.1) 
results in patency that is half of that achieved in the SCID/bg mouse (WT: 0.071+/-
0.035mm, SCID/bg: 0.804+/-0.039mm, SCID: 0.137+/-0.032mm, Asp/Pla: 0.452+/-
0.130mm, NKab: 0.356+/-0.151mm; P<0.001). We additionally show that SCID/bg mice 
show a blunted immune response to scaffold implantation, wheras wild-type mice show 
a dramatic initial burst of activity as demonstrated by macrophage number, mRNA, and 
cytokine levels. Implicating the initial innate immune response to the scaffold as a 
critical contributing factor in graft stenosis may provide a strategy for prognosis and 
therapy of future TEVGs.  
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Congenital heart disease is a significant cause of mortality and morbidity among 
pediatric patients, affecting approximately 9 newborns per 1000 births. It represents the 
leading cause of infant death due to congenital defects, and more than 30% of infants 
that die of congenital abnormalities have a cardiac defect (1).  
 
Single ventricle anomalies collectively comprise one of the largest groups of potentially 
fatal cardiac conditions. They include tricuspid atresia, pulmonary atresia, and 
hypoplastic left heart syndrome, all of which result in mixing of the pulmonary and 
systemic circulations with subsequent chronic hypoxia, volume overload of the single 
ventricle, and eventual heart failure.  Without correction, they associated with a 70% 
mortality rate in the first year of life, with the highest risk of death occurring within the 
first postnatal week (2). 
 
Advancement of the surgical therapy of these patients has drastically changed this 
course, with continued declines in mortality occurring even into modern times as 
further refinements are made. Deaths from single ventricle defects decreased by 65% in 
the interval 1979-1997 and occurred at progressively older ages (3).  
 
The treatment of choice remains staged surgical reconstruction (4), (5), whereby, in a 
series of operations, the pulmonary circulation is separated from the systemic 
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circulation, normalizing the volume delivered to the ventricle and preventing heart 
failure as well as improving systemic oxygenation. The deoxygenated blood is then 
passively circulated through the pulmonary circulation. This latter step is most 
commonly achieved through a modified Fontan operation, where a conduit is placed 
that connects the vena cava to the pulmonary artery. This modified Fontan procedure, 
the extra cardiac total cavopulmonary connection (EC TCPC), is considered the standard 
of care for patients with single ventricle anomalies.  
 
Polytetrafluoroethylene (PTFE or Gore-Tex®) conduits are currently the most widely 
used vascular grafts for EC TCPC (5). Long term data regarding the performance of these 
grafts is not yet widely available, but data regarding the long term performance of 
valved and unvalved conduits used in similar operations suggests that there may be 
complications in the future. Late problems encountered in these latter grafts include 
conduit degeneration with progressive obstruction, increased susceptibility to infection, 
and increased risk for thromboembolic complications (6). PTFE grafts also lack growth 
potential, necessitating re-operation when patients outgrow them. Re-operations are 
associated with significant morbidity and mortality (6). 
 
Tissue engineered vascular grafts (TEVG) hold great promise for surgical applications 
such as these in which a vascular conduit is required. The ideal TEVG, comprised of 
living, autologous tissue, would address the problems associated with the use of 
synthetic biomaterials. Since there should be no foreign materials present in the mature 
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TEVG, the risk of microbial adherence and infection would be reduced. As with native 
vessels, the anti-thrombogenic endothelial cell intima would greatly decrease the risk of 
thromboembolic complications. Perhaps most significantly, these grafts should possess 
the capability for growth and remodeling, effectively negating the necessity of re-
operation. 
 
In previous studies, using the classic tissue engineered paradigm, we implanted 
biodegradable scaffolds seeded with vascular cells as pulmonary artery grafts, and 
subsequently as IVC interposition grafts in ovine and canine models, to simulate the 
high flow, low pressure conditions of the EC TCPC conduit (7), (8). Over time, we have 
demonstrated the in-vivo degradation of the scaffold and the generation of a mature, 
laminated vascular structure that closely approximates native vessels. The neovessels 
formed in this fashion had an endothelial-lined intima, a media containing smooth 
muscle cells (SMCs), and an outer advential layer. Additionally, they showed evidence of 
growth and development, increasing in size proportional to the surrounding tissue (9).  
There was no evidence of failure associated with aneurismal dilation or thrombosis. 
 
The mechanisms underlying neovessel formation were incompletely understood, and it 
was assumed that the neotissue was formed as a result of repopulation of the scaffold 
from the seeded cells. Culturing vascular cells for autologous cell seeding proved to be a 
cumbersome process, requiring initial vein biopsy, as well as an extended culture period 
during which there was risk for contamination (10). Based upon reports that showed 
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that bone marrow mononuclear cells (BM MNCs) stimulated the endothelialization of a 
synthetic prosthesis (11), and that bone marrow derived endothelial progenitors were 
incorporated into areas of injury-induced neovascularization (12),(13), we theorized that 
BM MNCs might prove to be an easily accessible source for autologous cell seeding. This 
was borne out in our canine and ovine models, where BM MNC were harvested from 
the sternum, seeded upon polymer scaffolds, and implanted into the animals on the 
same day (10), (14), (15). 
 
Based upon the success of these animal models, we performed a pilot clinical study of 
autologous BM MNC-seeded TEVG as conduits in the modified Fontan procedure (16), 
(17), (18), (19). A total of 25 patients were enrolled in the study with a follow up of 7 
years. Serial MRI imaging confirmed the potential of the grafts for growth (18). There 
was no graft related mortality, and again, no complications associated with thrombosis 
or aneurysm. Four of the grafts, however, did develop complications from significant 
stenosis. These patients were treated successfully with angioplasty or angioplasty and 
stenting, since the neovessel conduits were amenable to coronary interventions that 
would have been impossible with synthetic grafts (19). To date, no graft has had to be 
replaced. This clinical trial demonstrated that tissue engineering has the potential to 
provide functional, growing grafts that avoid the pitfalls associated with synthetic 




To better understand the mechanisms by which stenosis, and indeed neotissue 
formation, takes place, we have developed sub-1mm scaffolds for implantation in a 
murine model (20). Advances in characterization and manipulation of mouse genetics 
make the murine host a good model for the study of these processes on a molecular 
level. Immunodeficient mice, in particular, allow for the direct study of human cell 
seeded scaffolds without fear of graft rejection.  
 
Using the SCID/bg mouse model, which lacks an adaptive immune response, we have 
recently studied the development of scaffolds seeded with human BM MNCs, and we 
have shown that the seeded cells do not give rise to neotissue directly, as has previously 
been thought (21). Rather, we have proposed that neotissue formation is a 
regenerative, immune-mediated process characterized by early degradation of BM 
MNCs, infiltration of the scaffold by monocytes, the secretion of cytokines such as VEGF, 
and the resultant recruitment of host endothelial and smooth muscle cells. In further 
studies which are in press, we have found that the host cells that populate the graft 
migrate laterally from adjacent native tissue (22). Additionally, we have found that the 
seeded BM MNCs function by a transient paracrine effect, modulating the immune 
response and accelerating the kinetics of neotissue formation (21). This is borne out by 
previous studies, where BM MNC-seeded grafts exhibited faster endothelialization, 
smooth muscle recruitment and collagen deposition than unseeded controls (15), (9). 
 
There are limitations to the use of this animal model which merit consideration. These 
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grafts are of a much smaller caliber than the grafts used in human applications, and are 
thus subject to different hemodynamic forces in-vivo, which may affect neotissue and 
stenosis formation. Animal models also have inherent species and strain specific 
characteristics that affect the applicability of their results to humans, or even to each 
other. In comparing the patency rates of autologous endothelial cell seeded synthetic 
grafts in dogs and lambs, for example, one study noted that the lambs had a much 
higher rate of thrombosis, with 89% of the grafts becoming occluded. The canine 
recipients, however, had a thrombosis rate of only 17% (23). 
 
In a similar fashion, our studies in SCID/bg mice have only yielded largely patent vascular 
grafts. Scaffolds seeded with human BM MNCs, human aortic smooth muscle cells, as 
well as ovine arteriole decellularized xenografts (24), (20), (25), (21), have all been 
implanted into SCID/bg mice, and were tolerated well. Recent studies which are in 
press, by contrast, have shown that the immunocompetent C57Bl6 mouse strain 
exhibits a similar rate of stenosis to humans (20%) when implanted with syngenic mouse 
BM MNC- seeded grafts (26). The rate of stenosis increases dramatically to 80% when 
the graft is unseeded. 
 
As stated above, our experiments in BM MNC seeded grafts have shown that the 
process of TEVG formation is an immune modulated process, and the differences in the 
occurrence of stenosis between the immunodeficient SCID/bg mouse and the 
immunocompetent C57Bl6 models is striking. We hypothesized that the formation of 
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stenosis was as a result of an exuberant inflammatory response, with excessive 
inflammation triggering excessive smooth muscle cell and extracellular matrix 
deposition. Seeding with BM MNC may serve to modulate this process and thus reduce 
graft stenosis. The two mouse models used, however, represent two different strains, 
with SCID/bg mice being mutants of an albino CB17 strain, while the C57Bl6 are 
normally pigmented variants. As previously noted, strain-specific differences in results 
cannot be neglected. In an attempt to better characterize the effect of 
immunodeficiency on rates of TEVG stenosis, here we compare grafts implanted in 
SCID/bg mice with grafts implanted into the wild-type CB17 background, and attempt to 
characterize the differences in immune response between the two. Unseeded grafts are 





Hypothesis and Specific Aims 
The formation of TEVG stenosis is as a result of an exuberant inflammatory response, 
and blunting this response in an immunodeficient mouse model, or by specific depletion 
of immune cell lines will abolish graft stenosis. 
 
Specific Aims 
1. To determine whether the immunodeficient SCID/bg mouse experiences lower 
rates of graft stenosis, and whether the cell line defects in T and B cells (SCID 
mutation) or NK cells  and platelets (Bg mutation) are responsible for this effect 
 
2. To determine whether a decreased hyperplastic response is reflected by a 





Immunohistochemistry, immunofluorescence and mouse anesthesia were performed by 
Dane Mejias. Scaffold fabrication and treatment of mice with aspirin, clopidogrel and NK 
1.1 antibody were performed by Dane Mejias and Narutoshi Hibino. Microsurgical 
implantation of scaffolds was performed by Tai Yi and Narutoshi Hibino. qPCR and RT-
PCR were performed by Narutoshi Hibino. 
 
Scaffold Fabrication 
Scaffolds were constructed from a nonwoven polyglycolic acid (PGA) mesh (Concordia 
Fibers) and a co-polymer sealant solution of poly-L-lactide and –ε-caprolactone 
(P(CL/LA)) using previously described methods (20) 
 
TEVG Implantation 
TEVG implantations were performed using microsurgical technique. The scaffolds were 
inserted into the infrarenal IVC of 3-4 month old, CB-17 backgound of wild type, 
SICD/bg, and SCID female mice (TECOIC). A total of 72 animals were implanted with 
TEVG. All animal experiments were done in accordance with the institutional guidelines 
for the use and care of animals, and the institutional review board approved the 
experimental procedures described. 
 
Histology  
Explanted grafts were pressure fixed in 10% formalin overnight and then embedded in 
paraffin or glycolmethacrylate using previously published methods (20),(21). H&E 
(Sigma, St Louis, MO) staining was conducted to evaluate graft morphometry. Graft 
luminal diameter were measured using Image J software (Image Processing and Analysis 




Primary antibodies included rat-anti-mouse F4/80 (AbD Serotec), mouse-anti-human 
Smooth Muscle Actin (SMA) (Dako), rabbit-anti-human vWF (Dako), and mouse-anti-
mouse NK 1.1 (Abcam). Antibody binding was detected using appropriate biotinylated 
secondary antibodies, followed by binding of streptavidin-HRP and color development 
with 3,3-diaminobenzidine (Vector). Nuclei were then counterstained with hematoxylin. 
For immunofluorescence detection, a goat-anti-rabbit IgG-Alexa Fluor 568 (Invitrogen) 
or a goat-anti-mouse IgG-Alexa Fluor 488 (Invitrogen) was used with subsequent 4',6-
diamidino-2-phenylindole nuclear counterstaining. 
 
Ultrasonography:  
Serial ultrasonography (Vevo® Visualsonics 770) was utilized for graft surveillance of the 
TEVG. Prior to ultrasonography, mice were anesthetized with 1.5% inhaled isoflurane. 
Graft luminal diameter was determined sonographically at the indicated time points 
after post-implantation. 
 
Micro-computed tomography angiography (microCTA):  
In vivo patency and morphology of the TEVG were evaluated using microCTA, as 




Computer Assisted Image Analysis (Quantitative IHC):  
Mouse macrophages, identified by positive F4/80 expression, were measured for each 
explanted scaffold. Two separate sections of each explant were counterstained with 
hematoxalin and imaged at 400X magnification. The number of nuclei was then counted 
in five regions of each section and averaged.  
 
qRT-PCR: 
RNA Isolation and qRT-PCR to Characterize Macrophage Phenotype: Explanted tissue 
grafts were frozen in Tissue-Tek OCT (Sakura) and each sectioned into forty 10um 
sections using Cryocut 1800 (Leica). Excess Tissue-Tek OCT was removed by 
centrifugation in water. RNA extraction was performed with an RNeasy Mini Kit 
(QIAGEN VWR, Stockholm, Sweden), according to the manufacturer’s protocol. RNA 
concentration of each sample was determined by Quant-iT™ RiboGreen® RNA Reagent 
and Kit (Invitrogen Co., Carlsbad, California, USA), according to the manufacturer’s 
protocol. Real-time reverse transcriptase polymerase chain reaction was carried out 
with a 50 µL total volume containing 1 µg RNA, 5 µL 10xTaq-Man RT Buffer, 11 µL MgCl2 
(25 mM), 10 µL dNTP mixture (10 mM), 2.5 µL Random Hexamer (50 mM), 1 µL RNase 
inhibitor (20 U/ µL ), and 1.25 µL reverse transcriptase (50 U/ µL ) (Applied Biosystems). 
RNAse-free water was added to bring total sample volume to 50 µL . The thermal cycling 
parameters were incubation at 25°C for 10 min, reverse transcription at 48°C for 30 min, 
and inactivation at 95°C for 5 min. Predesigned and validated gene-specific TaqMan 
Gene Expression Assays from Applied Biosystem (Foster City, CA, USA) were used in 
 16
duplicate for quantitative real-time PCR according to the manufacturer’s protocol. 
Primers for the following genes were used: CCL3 (Mm00441258_m1), iNOS 
(Mm00441258_m1), TNF-alpha (Mm00443258_m1), CX3CR1 (Mm00438354_m1), Fizz1 
(Mm00445110_g1), and MMP9 (Mm00600157_g1). Values were normalized to 
expression of HPRT (Mm00441258_m1). 
 
Platelet Inhibition 
Wild-type mice were treated with aspirin and clopidogrel for 10 weeks following TEVG 
implantation. Aspirin (30 mg/L) was placed in their drinking water, which was replaced 
with fresh water every other day. Considering that each animal drinks in average 3 to 4 
mL of water per day, this would be equal to 90 to 120 μg aspirin per day for a mouse of 
30-g of weight. This low quantity was administered to obtain an amount similar to that 
prescribed in clinical practice, i.e.,3–4 mg/kg/day (50), (51). Clopidogrel (Plavix) was 
obtained from the local hospital pharmacy, and 75-mg tablets were dissolved in 0.9% 
saline under sterile conditions. This solution was then diluted appropriately in 20 mg/kg 
clopidogrel. Daily treatment with clopidogrel was started immediately after 
transplantation. Because dissolved clopidogrel is unstable, the clopidogrel solution was 
freshly prepared every day and injected intraperitoneally immediately after preparation. 
(52) These mice were sacrificed at the end of the 10weeks treatment period, and the 




Natural Killer Cell Inhibition 
Wild type mice were treated with 200ul of NK 1.1 ab (ebioscience) at 2 days and 24 
hours prior to TEVG implantation, then weekly thereafter for 10 weeks. This dose of NK 
antibody were used to sustain depletion of NK cells from the spleen without reduction of 
cellular or humoral immunity. As above, these mice were sacrificed and the grafts 









We have previously demonstrated the feasibility of creating sub-1 mm 
biodegradable tubular scaffolds that are functional as vascular grafts in our previous 
study (20). Here, we investigated the natural course of the grafts using this same model. 
TEVG grafts implanted into SCID/bg mice were followed over 24 weeks. Histologic 
examination of the vessels at 1 week, 3 weeks, 6 weeks, 10 weeks and 24 weeks (N=4 
for each time point) demonstrated progressive infiltration of the structure by 
macrophages, degradation of the polymer scaffold, and the formation of a laminated 
neovessel (fig1a). Up to 3 weeks after implantation, the wall thickness increased and 
luminal diameter decreased due to the cell infiltration into the graft. Thereafter, the 
degradation of scaffold led to decreased wall thickness and increased luminal diameter, 
and both values closely approximated native IVC at 24 weeks (fig1c). 
Immunofluorescence staining demonstrated  vWF positive endothelial cell and alpha 
SMA positive cell layer in the inner layer of graft at 10 weeks following implantation 
(fig1b). This staining confirmed the presence of a confluent endothelialized intima and a 
medial smooth muscle layer at the 10 week time point, suggesting that this was an 





Fig 1. Characterizing neovessel formation in SCID/bg mice. A. H&E staining 
demonstrating infiltration of the scaffold wall with macrophages, and the serial 
degradation of the scaffold and neovessel formation (Bar=200um). B. 
Immunofluorescence of mature vessels showing positive staining for endothelial and 
smooth muscle cells. C, D, E Luminal diameter and wall thickness changes in the 
neovessels over time. 
 
To investigate the effect of host immune function on TEVG neotissue 
formation, we implanted 8 unseeded scaffolds into CB17 SCID/bg mice and 8 unseeded 
scaffolds into wild type CB17 controls. Ultrasonography demonstrated stenosis of the 
grafts implanted in wild type mice after 2 weeks whereas the grafts of SCID/bg group 
remained patent up to 10 weeks. Histologic examination at 10 weeks confirmed the 
development of stenosed grafts in the wild type mice, with severe intimal thickening. All 
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of the SCID/bg grafts, by contrast, remained patent and demonstrated significantly 
higher diameter compared with wild type (average luminal diameter (LD) WT: 0.071+/-





Fig 2. SCID/bg  mice show markedly increased patency rates vs wild type controls A. H&E 
stain of TEVG cross sections from wild type and SCID/bg CB17 mice (Bar=200um). C. 
Luminal diameters of SCID/bg implanted mice are higher than WT mice at 2, 4, 6, 8 and 
10 weeks post implantation. WT scaffolds show uniform occlusion at 8 weeks post-
implantation. B. and D. SCID/bg mice show increased luminal and vessel diameters after 
10 weeks vs WT controls. 
 
 
The SCID/bg phenotype is due to defects in T and B cell function (SCID 
mutation) and natural killer and platelet dysfunction (bg mutation). To ascertain 
whether defects in these cell lines could be independently responsible for decreased 
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intimal hyperplasia, we implanted scaffolds into mice that bore only the SCID mutation 
(SCID) (N=8), as well as into wild type CB17 mice that were treated with either an NK-
cell depleting antibody (NKab) (N= 8), or with platelet-inhibiting aspirin and clopidogrel 
(Asp/Pla) (N=6). Ultrasonography demonstrated a difference in luminal diameter at 2 
weeks following implantation. The SCID mice developed graft stenosis at a rate 
equivalent to WT mice, while each of the treated groups exhibited luminal diameters 
that were halfway between SCID/bg mice and the WT group. (WT: 0.071+/-0.035mm, 




Fig 3. A. H&E staining showing complete occlusion of a TEVG implanted into a SCID 
mouse, and patent grafts implanted into mice treated with aspirin and clopidogrel or an 
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anti-NK antibody (Bar=200um). B. and C. SCID-only mice display stenosis that mirrors 
the wild-type response. Mice treated with aspirin/clopidogrel or NK 1.1 antibody 




To further investigate the role of Natural Killer cells in intimal hyperplasia, we 
performed immuohistochemical analysis of the stenosed wild type grafts as well as the 
patent SCID/bg grafts using the anti-NK antibody NK 1.1. The stenosed grafts stained 
positive for Natural Killer cells, and in grafts that showed evidence of hyperplasia 
without complete stenosis, NK 1.1- positive cells were observed in the hyperplastic 
region. Scaffolds were subsequently implanted into pfp gene deficient mice which 
exhibit severe cytotoxic dysfunction of NK cells. As the background of this strain is 
C57/BL6, we explanted scaffolds at 2 weeks that is the optimal end point to examine the 
patency of graft based on our previous study (26). There was no significant difference in 
luminal diameter, however, between these mice and the wild type controls. This result 
suggested that not cytotoxic function but cytokines secreted from NK cell could be an 
important factor causing  graft stenosis. 
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Fig 4. A. IHC staining with NK 1.1 antibody showing that NK cells are present at sites of 
neointimal hyperplasia. B. SCID/bg mice show no positive staining with NK 1.1. C. NK-KO 
mouse show no significant differences in luminal diameter when compared to wild-type 
controls. 
 
Although SCID/bg mice do not typically exhibit a pronounced defect in the innate 
immune response, we nonetheless investigated the difference in macrophage 
recruitment response between the SCID/bg mice (N=8) and WT CB17 (N=8) mice 
through semi-quantitative assessment of the degree of macrophage infiltration. The 
SCID/bg mice showed significantly less macrophages per high-powered field (WT: 113+/-
12 /HPF, SCID/bg: 66+/-18/HPF; p=0.006). This result is consistent with the result of PCR 
analysis of scaffold at 3 days, which showed significantly less F4/80 mRNA production in 




Fig 5. A. Immunohistochemistry of wild-type CB17 mice demonstrating more robust 
macrophage infiltration than in SCID/bg mice, B. C. SCID/bg mice show fewer 
macrophages than wild-type mice upon semi-quantitative analysis. D. RT-PCR 
demonstrating less macrophage cellular activity in SCID-bg mice 
 
The decreased macrophage activity in the SCID/bg grafts suggested that there is less 
inflammatory cytokine production, and evidence of a blunted immune response to the 
implanted scaffold. To further explore this, we performed PCR for CCL3 (a macrophage 
recruitment and activation protein), iNOS (an anti-inflammatory cytokine) and TNF-
alpha (an inflammatory cytokine) in SCID/bg and WT grafts at both an early 3 day and a 
later 4 week time point. For the 3 day time point, a sharp initial production of all of 
these cytokines was demonstrated in the WT mice, but not the SCID/bg mice. These 
levels all decreased by the 4 week time point in the WT mice, while the SCID/bg mice 
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showed minimal declines. We also examined the levels of CXCL1 and Fizz, which 
represent makers of the later reparative macrophage response as well as MMP9, an 
extracellular matrix degrading enzyme which is thought to play a role in tissue 
remodeling. Levels of these proteins could be expected to be higher in a hyperplastic 
response, with an exaggerated remodeling response resulting in the creation of a 
hyperplastic neointima. By contrast, our results demonstrated a slightly higher 
expression of CX3CL1 in the SCID/bg mice, and comparable levels of Fizz and MMP9 in 
both groups.  
 
 
Fig 6. A-C. Wild-type mice show a greater initial inflammatory response after graft 
implantation, which drops rapidly by the 4th week. SCID/bg mice show only slight 
decreases in cytokine activity after 4 weeks. D-F. Markers of the later macrophage 
response and MMP9. CX3CL1 is slightly higher in SCID/bg mice after 4 weeks wheras Fizz 





The results of this study highlight the critical role that the immune system plays in TEVG 
stenosis. We have recently proposed a mechanism for the natural history of neotissue 
formation within bone marrow mononuclear cell (BM MNC) seeded scaffolds in SCID/bg 
mice, and surmised that it is an immune-mediated process (21). The process begins with 
the infiltration of the scaffold by host macrophages, which degrade the polymer scaffold 
while secreting angiogenic cytokines and growth factors, such as VEGF. This results in 
the recruitment of smooth muscle cells and endothelial cells, with eventual neovessel 
formation. BM-MNC secreted MCP-1, a monocyte chemoattractant protein, speeds up 
the kinetics of both macrophage recruitement and neovessel formation (21). Here, we 
assert that an overly robust burst of inflammation may be at the core of neovessel 
stenosis. 
 
This model, of a macrophage inflammatory response, followed by cell recruitment and 
remodeling, mirrors exactly the model that has been proposed for the formation of 
intimal hyperplasia, which is a well known pathologic process that causes arterio-venous 
graft failure in hemodialysis grafts (27), (28), and in coronary artery restenosis following 
angioplasty and stenting (29). The primary inciting factor that precipitates intimal 
hyperplasia appears to be vessel wall/endothelial damage as a result of surgical or 
interventional trauma, and in the case of hemodialysis AV grafts, graft 
bioincompatibility (30).  These upstream events provoke a cascade of events comprising 
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an acute inflammatory phase with macrophage infiltration, a proliferation phase with 
smooth muscle cell recruitment, and a remodeling phase (31). Presumably in the case of 
TEVGs, bioincompatibility, as well as the surgical anastamosis of the scaffold to the 
vasculature, would provide an ample stimulus for activation of the immune system, and 
provoke a similar sequence of events. 
 
In previous studies, the magnitude of the inflammation that occurs following vessel 
injury appears to be linked to the subsequent intimal hyperplastic response. Sustained 
high levels of systemic inflammation markers such as CRP predict increased risk of 
human coronary artery stenosis following stenting (32). The number of monocytes 
recruited to the vessel wall has also been directly correlated with the volume of 
neointima formation (33). Studies have shown that MCP-1 is an essential chemokine in 
this process, and that blockade of MCP-1 abrogates both macrophage recruitment and 
intimal hyperplasia (34), (35), (36). 
 
Inflammation has thus clearly been implicated in vascular hyperplasia in response to 
vessel injury. In the context of TEVG formation we propose, however, that inflammation 
is not purely pathogenic—and is in fact critical for neotissue generation—but that an 
overly exuberant inflammatory response causes excessive recruitment of SMCs, and 
resulting intimal thickening. We have currently submitted for review a study that further 
supports this idea. Pharmacologic inhibition of macrophages results in grafts that show 
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no stenosis, but also show a lack of neotissue formation (26). A balanced immune 
response is required for optimum TEVG development. 
 
SCID/bg mice, by virtue of their genetic derangements, appear to have this near-
optimum internal mileu. Though we hypothesized that an immunodeficient mouse 
would enjoy greater TEVG patency rates than an immunocompetent control, the 
contrast between the SCID/bg and wild-type mice is startlingly pronounced (Fig 1.). Wild 
type mice develop uniformly stenosed grafts, and the immunodeficient mutant develops 
uniformly patent, though fully cellularized and mature neovessels (Fig 1., Fig 2.). 
Additionally, the exuberant stenosis exhibited in wild type CB17 mice is beyond that 
observed in humans, or indeed in other animal models (18), (26). The exaggerated 
response of this mouse species, and that of its immunodeficient variant, lie on the 
extreme ends of the spectrum of intimal hyperplasia in TEVGs. They provide a unique 
window through which the mechanisms that underlie this process can be viewed. 
 
In investigating what characteristics make the SCID/bg mouse resistant to graft stenosis 
we have attempted to separate the component cell line defects present. To this end, we 
implanted scaffolds in SCID- only mice that lack an adaptive immune response due to 
defective T and B cells. We have also implanted mice treated with anti-platelet agents 
aspirin and clopidogrel, and mice treated with an NK-neutralizing antibody, to mimic the 
platelet and natural killer cell defects present in the bg mutation. 
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In this study, T and B cells have appeared to play no role in abrogating TEVG intimal 
hyperplasia. This is in line with studies done in cyclosporine- suppressed rabbits (37), 
where suppression of humoral immunity had no effect, though at odds with studies 
done in athymic and T-cell depleted rats (38), (39). The latter two studies, however, 
have shown opposite results. The mixed evidence of the role played by the adaptive 
immune system may be due to species-specific differences, as well as differences in the 
method of diminishing the adaptive immune response. Nonetheless, in our study SCID 
mice demonstrated uniform occlusion of the graft, with no difference between these 
and wild-type CB17 mice. 
 
The inhibition of platelets and natural killer cells, by contrast, appeared to individually 
reduce stenosis rates to half of the rates expected of a SCID/bg mouse (Fig 3), implying 
that the beige mutation underlies the suppression of graft stenosis. The beige mutation 
is characterized mainly as a deficiency of granular cells, with decreased anti-microbial 
efficacy of granulocytes (40), severe NK cell deficiencies (41), and defective platelet 
function (42), (43). It is thought to be analogous to Chediak- Higashi syndrome in 
humans. Though the molecular underpinnings of this mutation remain to be elucidated, 
it appears to be a deficiency of the innate immune response. A defect of the innate, not 




Additionally, previous studies have implicated platelet adherence to damaged 
endothelium, and subsequent macrophage recruitment, as being a critical factor in the 
formation of a hyperplastic intima. Platelet P-Selectin expression is necessary for 
triggering monocyte arrest and adhesion, and P selectin -/- knockout mice demonstrate 
markedly decreased macrophage infiltration, as well as a subsequent decrease in intimal 
hyperplasia (44), (45). Direct blockade of P-selectin binding by sialyl-LewisX substrate 
replicates this response (46). Here, inhibition of platelets by pharmacologic means has 
decreased the degree of stenosis in TEVGs (Fig 3.). That SCID/bg mice also show 
decreased macrophage recruitment (Fig 5.) would be commensurate with this. Aspirin, 
as an NSAID drug, also possesses anti-inflammatory properties that might confound 
these results, but the standard dose used is thought to be below the threshold at which 
the anti-inflammatory effects become apparent. We have also tried to substantiate the 
importance of platelets by direct anti-thrombocyte antibody depletion following 
scaffold implantation, but this proved to impair the hemostatic capabilities of the mice 
beyond the limit to which they could survive the implantation procedure. The decrease 
in stenosis as a result of administration of readily available anti-platelet medications, 
however, does have implications for therapy of TEVG recipients. 
 
Evidence in our study regarding the role of natural killer cells in graft stenosis is mixed. 
Antibody treatment of mice with NK 1.1 appeared to have a beneficial effect on graft 
patency (Fig 3.), but scaffolds implanted into NK KO mice showed no difference from 
their wild-type counterparts (Fig 4.). In the literature, NK cells have been demonstrated 
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to promote arteriogenesis in a murine hindlimb ischemia model (47), while Cd1d-/- mice, 
which have faulty lipid antigen presentation to NK cells, have shown a 60% decrease in 
intimal hyperplasia in a carotid artery injury model (48). In this study, it is certainly 
possible that the NK 1.1 antibody exerted its effect through NK inhibition as expected, 
and that the NK KO mouse possesses other genetic derangements that negated the 
effect of defective NK cells. It is however, equally possible that the antibody exerted its 
effect through an indirect means. Reconciling this discrepancy brings into focus one of 
the limitations of the immunodeficient mouse models used in this study—namely that 
while the gene mutations do have a significant effect on immune cell lines, there may be 
unforeseen consequences on other biochemical pathways. 
 
Whatever the individual molecular derangements of the SCID/bg mouse, a clear 
contrast in the initial innate inflammatory response to graft can be drawn between 
these mice and their wild type counterparts. In broad strokes, this is represented by 
both a decrease in overall macrophage number by quantitative histology, as well as by a 
lower level of macrophage mRNA production (Fig 5.).  
 
Commensurate with this, our more specific PCR analysis (Fig 6) demonstrated that the 
macrophage recruitment cytokine CCL3 was higher in the wild type than SCID/bg 
groups, as was the proinflammatory cytokine TNF-alpha. The anti-inflammatory iNOS 
was also higher in the wild type mice than in the SCID/bg group. As iNOS plays a role in 
the modulation of inflammation (49), this suggests that there is certainly greater 
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inflammatory activity in the wild-type mice, with both proinflammatory cytokines and 
their anti-inflammatory modulators being engaged. This discrepancy is only apparent at 
the 3 day time point; by 4 weeks, when stenosis has already become apparent (Fig 1.), 
all of these cytokines have fallen to levels that are comparable with the levels seen in 
SCID/bg mice, with only a modestly higher level of CCL3 and a modestly lower level of 
iNOS in the wild type mice vs. SCID/bg. Also of note is the near-constant profile of these 
cytokines in SCID/bg mice at 3 days and four weeks. Where wild type mice show an 
initial upswing of inflammatory activity after vessel implantation followed by a sharp 
decline, the SCID/bg mice show negligible changes of these cytokine levels during the 
four week time course. 
 
Our findings with regard to “late” markers of inflammation—CX3CL1, Fizz, and MMP, 
which are thought to represent the later remodeling response—are less striking. Both 
wild type and SCID/bg mice show comparable responses (Fig 6.). It appears that it is not 
the remodeling phase but the inflammatory phase, or lack thereof, that is unique to the 
SCID/bg mice. 
 
We surmise that it is the initial burst of inflammatory activity that correlates with 
stenotic grafts in the wild type CB17 mice, whether this is as a direct result of impaired 
platelet and natural killer activity or no. Our parallel study that shows a causative role of 
macrophage infiltration in neotissue formation and intimal hyperplasia is consistent 
with this. Further characterization of the molecular determinants of this initial response 
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could, at the least, provide a measurable predictor of graft patency. Furthermore, this 
has implications for the rational design of second generation TEVGs. We have already 
demonstrated the ability to construct cytokine-eluting scaffolds (21). Future graft 
designs may include, in a similar fashion, the ability to elute appropriately targeted anti-
inflammatory, and possibly, anti-thrombotic agents that will increase the utility of 
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